Skip to main content
Fig. 1 | BMC Medical Genomics

Fig. 1

From: Promoter hypermethylation and comprehensive regulation of ncRNA lead to the down-regulation of ZNF880, providing a new insight for the therapeutics and research of colorectal cancer

Fig. 1

ZNF880 protein structure and its expression in pan-cancer and cancer staging. A: The ZNF880 protein structure predicted by AlphaFold, which has typical KRAB and C2H2 domains. B: The expression level of ZNF880 in pan-cancer. BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma mutiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma. C: The expression level of ZNF880 in READ and COAD. D: The expression level of ZNF880 in CRC cancer staging

Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us